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Abstract
Vitamin D signaling in mammary cancer stem cells (MCSCs), which are implicated in the initiation and progression of breast
cancer, is poorly understood. In this study, we examined vitamin D signaling in mammospheres which are enriched in
MCSCs from established breast cancer cell lines. Breast cancer cells positive for aldehyde dehydrogenase (ALDH+) had
increased ability to form mammospheres compared to ALDH2 cells. These mammospheres expressed MCSC-specific
markers and generated transplantable xenografts in nude mice. Vitamin D receptor (VDR) was significantly down-regulated
in mammospheres, as well as in ALDH+ breast cancer cells. TN aggressive human breast tumors as well as transplantable
xenografts obtained from SKBR3 expressed significantly lower levels of VDR but higher levels of CD44 expression. Snail was
up-regulated in mammospheres isolated from breast cancer cells. Inhibition of VDR expression by siRNA led to a significant
change in key EMT-specific transcription factors and increased the ability of these cells to form mammospheres. On the
other hand, over-expression of VDR led to a down-regulation of Snail but increased expression of E-cad and significantly
compromised the ability of cells to form mammospheres. Mammospheres were relatively insensitive to treatment with 1,25-
dihydroxyvitamin D (1,25D), the active form of vitamin D, compared to more differentiated cancer cells grown in presence of
serum. Treatment of H-Ras transformed HMLEHRas cells with DETA NONOate, a nitric oxide (NO)-donor led to induction of
MAP-kinase phosphatase -1 (MKP-1) and dephosphorylation of ERK1/2 in the mammospheres. Combined treatment of these
cells with 1,25D and a low-concentration of DETA NONOate led to a significant decrease in the overall size of
mammospheres and reduced tumor volume in nude mice. Our findings therefore, suggest that combination therapy using
1,25D with drugs specifically targeting key survival pathways in MCSCs warrant testing in prospective clinical trial for
treatment of aggressive breast cancer.
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Introduction
Compelling evidence has emerged that normal vitamin D levels
are associated with reduced rates of various types of cancer,
including breast tumors, in addition to its various other important
functions [1]. Vitamin D insufficiency has been found in 76% of
women with breast cancer and higher levels of vitamin D intake
have been found to be associated with reduced risk and improved
prognosis in breast cancer patients [2]. Vitamin D receptor (VDR)
gene polymorphisms have also been shown to modify breast
cancer susceptibility [3–5]. However, breast cancer cells that
express functional estrogen receptor (ER+) also have high
expression of VDR and display enhanced sensitivity to treatment
with the active form of vitamin D (1,25-dihydroxyvitamin D,
1,25D) [6–7]. Poorly differentiated (ER2) breast cancer cell lines
express less VDR and are less sensitive to 1,25D administration
[7].
High numbers of mammary cancer stem cells (MCSCs) are
found in higher grade aggressive and undifferentiated breast
tumors compared to the differentiated lower grade tumors [8–10].
MCSCs also express embryonic stem (ES) cell-specific gene sets
and arise from mammary stem cells (MSCs), where self-renewal/
differentiation mechanisms are deregulated [11]. In addition to
driving aggressive tumors, MCSCs have also been implicated in
recurrence of less aggressive ER+ breast tumors following
treatment [12–13]. Although primary tumors usually respond
well to various therapeutic regimens, including 1,25D treatment,
recurrent tumors are more aggressive and resistant [14]. The
sensitivity of MCSCs to 1,25D treatment remains poorly un-
derstood and is the focus of this report.
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In the current study, we used in vitro and in vivo approaches to
examine the molecular mechanisms that regulate 1,25D sensitivity
in mammospheres isolated from breast cancer cell lines. Our
results indicate that mammospheres isolated selectively from
established breast cancer cells have suppressed VDR signaling,
increased expression of CD44 [15], and decreased sensitivity to
1,25D administration. Incubation with low concentrations
(300 mM) of the nitric oxide (NO)-donor DETA NONOate)
(which induces MAP-kinase phosphatase-1 and dephosphorylates
ERK1/2 increased the sensitivity of mammospheres to 1,25D
administration in vitro, and significantly reduced tumor volume in
nude mice in vivo. Our data therefore, provides evidence that
vitamin D or its analogs may be more effective as an adjuvant
therapy, when used in combination therapy with other compounds
known to effectively target key survival pathways in MCSCs.
Materials and Methods
Reagents and Cells
Basic human recombinant fibroblast growth factor (FGF) and
recombinant human epidermal growth factor (EGF) were
purchased from Calbiochem (San Diego, CA). 1,25(OH)2 D3
(1,25D) was obtained from Enzo Life Science (Plymouth, PA).
Insulin, cholera toxin, and hydrocortisone were purchased from
Sigma chemicals. DETA-NONOate was from Cayman Bio-
chemical (Ann Arbor, Michigan). Human breast cancer cell lines
MCF-7 and SKBR3 were obtained from ATCC (Rockville, MD).
SKBR3 cells were cultured in RPMI 1640 (Sigma, St. Louis, MO)
supplemented with L-glutamine and 10% fetal bovine serum
(FBS). MCF-7 cells were cultured in DMEM containing sodium
pyruvate, 10 mM non-essential amino acids, 2 mM L-glutamine,
10 g/ml insulin, and 10% FBS. HMLE and HMLEH-RAS were
obtained from Robert Weinberg (Whitehead Institute at MIT,
Cambridge, Massachusetts). HMLE and HMLEH-RAS (HRas)
were cultured in DMEM: Ham’s F-12 (1:1) supplemented with
10% FBS, 10 mM HEPES, 10 mg/ml insulin, 20 ng/ml EGF,
100 ng/ml cholera enterotoxin, and 0.5 mg/ml hydrocortisone.
Mammosphere Formation
Mammosphere growth assays were carried out as described
[16]. Cell lines were trypsinized and suspended in serum-free
mammosphere media (MSM) comprised of DMEM: Ham’s F-12
(1:1) supplemented with 10 mM HEPES, 5 mg/ml insulin, 20 ng/
ml EGF and 10 ng/ml basic FGF. Cells were counted and 50,000
cells/well were plated in ultra-low attachment 6-well plates
(CostarTM 3471).
Immunofluorescence
Cells were fixed and prepared for immunofluorescence as
previously described [17]. Primary antisera were used at 0.5–
1 ug/ml. CD44 (10432), and CD24 (10424) were purchased from
Stem Cell Technologies. ESA (E1591) was purchased from
Ventana (Freemont, CA). MKP-1 and pERK1/2 antibodies were
obtained from Santa Cruz Biotech (Santa Cruz, CA) and Cell
Signaling (Danvers, MA) respectively. Secondary antisera included
highly cross adsorbed goat anti-rabbit Alexa-633, goat anti-rabbit
Alexa-488 or goat anti-mouse Alexa-488 (A31619) were obtained
from Life Technology (Carlsbad, CA). Cells were counterstained
with 6-diamidino-2-phenylindole (DAPI, Molecular Probes) and
data were analyzed using Openlab 5.0 software (Improvision) [17].
Aldefluor Assay and Flow Cytometry
To measure and isolate cells with high ALDH activity, the
Aldefluor assay was carried out [16] according to manufacturer’s
(Stem cell Technologies) guidelines. Briefly, breast cancer cells
were suspended in Aldefluor assay buffer containing an ALDH
substrate, bodipy-aminoacetaldehyde (BAAA) at 1.5 mM, and
incubated for 40 min at 37uC. To distinguish between ALDH+
and ALDH2 cells, a fraction of cells was incubated under identical
condition in the presence of a 10-fold molar excess of the ALDH
inhibitor, diethyl amino benzaldehyde (DEAB). This results in
a significant decrease in the fluorescent intensity of ALDH+ cells
and was used to compensate the flow cytometer.
PCR Array Analysis
Aliquots of total cellular RNA isolated with Trizol reagent from
SKBR3 and HRas cells grown under plastic and mammospheres
conditions were subjected to RT2 profiler PCR Array [Human
Epithelial to Mesenchymal Transition (EMT), PAHS-090A; SA
Bioscience, Frederick, MD] analysis. This PCR Array contains
pre-dispensed primer sets for the specified genes into a 96-well
PCR plate designed to study the expression profiles of 84 genes
related to EMT. Raw data were analyzed using PCR Array Data
Analysis, and fold changes in relative gene expression were
presented after background correction and normalization with
a house-keeping gene [18] using DDCt method following the
manufacturer’s instruction (SA Bioscience, Frederick, MD).
Quantitative mRNA expression by Real time PCR
Total RNA was extracted from cultured cells using Trizol
method. cDNAs were synthesized from 1 mg total RNA using
GeneAmp RNA PCR core kit (Applied Bio systems N808-0143)
and 10 times diluted cDNA was used for PCR template. Human
PCR primers were designed and obtained from Primer Bank DNA
Core facility (http://pga.mph.harvard.edu/primerbank, MGH
Harvard, Cambridge, MA). The following primer sets were used
- c-Myc (139 bp), 306–328/444–424 on AF534403; Klf-4 (54 bp),
13–31/66–47 on NM_004235; Oct-4 (78 bp), 157–175/234–214
on NM_001159542; Sox-2 (200 bp), 121–140/320–301 on
NM_006943; VDR (60 bp), 605–627/664–644 on NM_000376;
RXR (69 bp), 45–65/113–92 on AY267839; Cyp24 (108 bp),
145–163/252–232 onNM_001128915; Cyp27 (78 bp), 157–175/
234–214 on NM_000784; and GAPDH (70 bp), 408–430/477–
459 on NM_002046. The protocol includes melting for 15 min at
95uC, 40 cycles of three-step PCR including melting for 15 sec at
95uC, annealing for 30 sec at 58uC, elongation for 30 sec at 72uC
with an additional detection step of 15 sec at 81uC, followed by
a melting curve from 55–95uC at the rate of 0.5uC per 10 sec;
annealing was at 55uC and detection was at 76uC. Samples of
25 ng cDNA were analyzed in quadruplicate in parallel with b-
actin controls; standard curves (threshold cycle vs. log pg cDNA)
were generated by log dilutions of from 0.1 pg to 100 ng standard
cDNA, and then experimental mRNA starting quantities were
calculated from the standard curves and averaged using i-Cycler,
iQ software as described previously. The ratios of marker
experimental gene to GAPDH mRNA were computed and
normalized to control (untreated) samples as 100% [17].
Down-regulation of VDR Expression in SKBR3 cells by
Small Interfering RNA (siRNA)
VDR levels were down-regulated in SKBR3 cells using VDR
small inhibitory RNA (siRNA) using standard techniques as before
(18). Human VDR gene was targeted by using ON-TARGET plus
SMART pool siRNA which consists of four siRNA sequences–
siRNA1 59GCAACCAAGACUACAAGUA39, siRNA2
59GCGCAUCAUUGCCAUACUG39, siRNA3 59CCAACACA-
CUGCAGACGUA39, and siRNA4 59GCAAUGAGAUCUC-
Vitamin D Receptor and Breast Cancer Stem Cells
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CUGACU39 (Dharmacon, Lafayette, CO, Cat# L-003448-00-
0005). These pooled siRNAs were used at 100 nM concentrations
with standard transfection protocol using lipofectamine 2000
(Invitrogen, Carlsbad, CA). Random siRNA (100 nM) was used as
a control. We were able to get ,75–80% inhibition of VDR
protein expression.
Over-expression of Full-length VDR in SKBR3 cells
VDR was over-expressed in SKBR3 cells by transient trans-
fection using Myc-DDK-tagged human VDR ORF clone
(NM_001017535) (Cat# RC219628) obtained from Origene
Technologies (Rockville, MD) using standard techniques. Briefly,
2.56105 cells were plated per well on a 6-well plate 24 hrs prior to
transfection. 1.5 mg of control vector or VDR clone was mixed
with lipofectamine 2000 (1:3) and cells were incubated overnight
after transfection. Next day, medium was replaced with fresh
complete growth medium and cells were allowed to grow for
another 24 hrs. VDR protein expression was analyzed by western
blot analysis to confirm the transgene expression.
Immunoblot Analysis of Cells and Patient Tissue Samples
Tumor samples from triple negative (TN) (ER2, PR2, Her22)
and estrogen receptor positive (ER+) tumor patients were obtained
from the following sources- a) Cooperative Human Tissue
Network (CHTN) (http://chtn.nci.nih.gov), (tumor samples were
collected using NCI funded resource under OHRP guidelines and
waiver of consent (45CFR46.101b) for anonymized samples; b)
National Disease Research Interchange (NDRI) (http://
ndriresourse.org) (approved biomedical research and IRB proto-
cols from consented breast tumor patients) and c) Breast tumor
and Tissue Repository at University of California, Los Angeles
(UCLA) (approved biomedical research and IRB protocols from
consented breast tumor patients). The research protocol was
approved by the Charles Drew University Institutional Review
Board (IRB) (permit number: 09-08-2229-03). Protein lysates (30–
75 mg) were resolved on 10–12% SDS-PAGE gels, electro-
transferred and analyzed for protein expression using the following
antibodies- VDR (D-6, sc-13133 Santa Cruz Biotech), RXR-a (D-
20, sc-553, Santa Cruz Biotech), CD44 (cat# 3570, Cell Signaling)
ERK1/2 (New England Biolab Inc., Ipswich, MA), pERK1/2
(9121L, Cell Signaling), MKP-1 (Sc-8599; Santa Cruz Bio-
technology) and GAPDH (Chemicon International Inc., Teme-
cula, CA) and appropriate HRP-linked to secondary antibodies
(1:1000 dilution) (Amersham Corp., Piscataway, NJ). Immunore-
active bands were visualized, scanned and analyzed by Image
Quant software [17].
Analysis of 25D Metabolites
Analysis of 25D metabolites was performed as described
previously [19]. Briefly, aliquots of cells were incubated with
radiolabeled 25(OH)D substrate (3H-25(OH)D, 5 nM) for 5 hrs in
serum-free culture medium. The resulting mix of 3H-vitamin D
metabolites was then extracted from the total cell lipids using
initial Sep-pak purification and subsequent HPLC analysis of 1a-
hydroxylated and 24-hydroxylated vitamin D metabolites. Direct
quantification of 3H-25(OH)D, 3H-1,25(OH)2D and
3H-
24,25(OH)2D utilizing an in-line radiodetector was used to
quantify 1a- and 24-hydroxylase activities. Data were reported
as fmoles of vitamin D metabolite produced per hr per mg cellular
protein.
Xenotransplants
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee (IACUC) on the Ethics of Animal Experiments of the
Charles Drew University of Medicine and Science (permit
number: I-1103-261). All surgery was performed under isoflurane
anesthesia, and all efforts were made to minimize suffering. Eight
week old nude mice were purchased from Harlan Laboratories
Inc. (Placentia, CA). Mammary glands of the mice were cleared of
endogenous epithelium and humanization of the fat pad was done
by injecting irradiated (4 Gy) fibroblasts from human tumors
(50,000 cells/100 ml matrigel/fat pad). After two weeks, 105
dissociated cells (suspended in 100 ml matrigel/fat pad) obtained
from mammospheres after various treatments were injected into
the humanized fat pad of nude mice (12 mice/group) and tumor
growth was monitored. Measurements were obtained by caliper
length and width measurements at weekly intervals for the
duration of the experiment. Tumor volume was calculated as K
(length6width2) [20].
Statistical Analysis
Data are presented as mean+/2 SD, and between group
differences were analyzed using ANOVA. If the overall ANOVA
revealed significant differences, then pair-wise comparisons
between groups were performed by Newman-Keuls multiple
group test. All comparisons were two-tailed and p values
#0.05 were considered statistically significant. The experiments
were repeated at least three times, and data from representative
experiments are shown.
Results
Isolation of Mammospheres with Mammary Cancer Stem
Cell Properties from Breast Cancer Cell Lines
We examined the mammosphere formation capability of several
breast cancer cell lines SKBR3 (Figure 1A, left panel), MCF-7 and
HMLEH-RAS and human mammary epithelial (HMLE) cells (data
not shown) by culturing them in defined mammosphere media on
ultra-low attachment plates. Well-defined heterogeneous popula-
tions of mammospheres were obtained from all these cell lines at
varying frequencies (1 in every 200–500 cell). Interestingly,
SKBR3 cells had the highest frequency of mammosphere
formation among various cell lines studied. The self-renewal
capability of the mammospheres was examined by repeatedly
dissociating the spheres (typically at day 5 of growth) and following
the life span by serial passage in mammosphere conditions.
Analysis of cell surface antigens showed strong expression of
cancer stem cell antigens CD44 and epithelial-specific antigen
(ESA) in SKBR3 mammospheres, whereas expression of CD24,
epithelial cell marker was low (Fig. 1A, right panel). Expression of
key transcription factors Sox2, Oct4, Klf4 and c-Myc, were
significantly up-regulated in the mammospheres isolated from
SKBR3 breast cancer cells (Fig. 1B). As the ALDH+ population
has been demonstrated to be enriched in mammary cancer stem
cells, we isolated ALDH+ and ALDH2 cell population by cell
sorting (FACS) (Figure 1C, left panel) and analyzed their efficiency
to form mammospheres. We found that ALDH+ cells had
significantly higher mammosphere forming capability (,one per
25 cells) compared to that of ALDH2cells (,one per 140 cells)
(Figure 1C, right panel).
Studies were also carried out to determine the in vivo enrichment
capacity of stem cell populations in mammospheres isolated from
Vitamin D Receptor and Breast Cancer Stem Cells
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SKBR3 cells. Xenograft formation (5/12) was induced in nude
mice by injecting 105 cells from dissociated SKBR3 mammo-
spheres in the humanized mammary fat pads of nude mice for 8
weeks (Figure 1D). When a similar number of more differentiated
cells grown on plastic were injected, there was no apparent tumor
formation within this time period (Figure 1D).
Figure 1. A: Left Panel: Bright field photomicrograph of mammospheres isolated from SKBR3 CELLS. Right Panel: Fluorescent
micrographs of SKBR3 mammospheres stained with CD44, ESA, and CD24 antigens (green) and DAPI (blue). B, Real-time quantitative PCR analysis of
c-Myc, Klf4, Oct4, and Sox2 in SKBR3 cells grown under high attachment, plastic (plas) or mammosphere (mam) conditions (*, p#0.05; **, p#0.01). C,
Isolation of ALDH+ and ALDH2 population from SKBR3 cells and analysis of their mammosphere forming capacity. D, Analysis of tumor volume in
nude mice by SKBR3 mammospheres and plastic cells. 16105 cells obtained from dissociated mam or plas were injected into the humanized
mammary fat pads of female nude mice and tumor volumes were analyzed at various time points (1–8 weeks).
doi:10.1371/journal.pone.0053287.g001
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PLOS ONE | www.plosone.org 4 January 2013 | Volume 8 | Issue 1 | e53287
Vitamin D Signaling is Selectively Down-regulated in
Mammary Cancer Stem Cells
We next examined expression of VDR in breast cancer cells
grown as mammospheres or as more differentiated cells grown on
high attachment plates. Significantly reduced levels of VDR
protein were found in mammospheres isolated from SKBR3
(78.467.6%), MCF-7 (68.269.6%) and HRas (81.469.2%) cells
compared to more differentiated cells grown in plastic (Figure 2A).
Protein expression of RXR, a nuclear receptor that hetero-
dimerizes with VDR, was also significantly down-regulated in
mammospheres from SKBR3 (68.6611.2%), MCF-7
(58.5614.4%) as well as HRas (7866%) cell lines compared to
more differentiated cells (Figure 2A). However, there was no
significant difference between VDR and RXR protein expression
in mammary epithelial HMLE cells propagated either as mammo-
sphere or plastic (Figure 2B). Comparison of gene-expression
between plastic and mammosphere cultures also suggests that
VDR mRNA was significantly down-regulated in mammospheres
isolated from breast cancer cells (MCF7:56.264.6%;
SKBR3:59.566.2%; and HRas: 72.463.5%) compared to cells
grown on plastic; however, there was no significant difference in
VDR expression between mammospheres and plastic cultured
cells isolated from mammary epithelial HMLE (Figure 2C).
Selective Induction of Snail in Mammospheres Obtained
from Breast Cancer Cells
Expression of the transcription suppressor Snail was assessed in
mammospheres and cells grown on high attachment plates from
MCF7 and SKBR-3 as well as from HMLE cells. Snail was
significantly up-regulated in mammospheres isolated from SKBR3
(6.861.2 fold) and MCF7 (4.160.3 fold) cells compared to
equivalent cells cultured on plastic (Figure 2D, left and middle
panel). On the other hand, there was no significant difference in
Snail expression between mammosphere and plastic groups in
HMLE (Figure 2D, right panel).
Up-regulation of Epithelial to Mesenchymal Transition
(EMT) Gene Signature in Mammospheres
Since Snail, one of the well-known inducers of EMT was found
to be up-regulated in mammospheres isolated from breast cancer
cells; we compared EMT gene signature in SKBR3 cells grown
under plastic and mammospheres conditions. We initially utilized
EMT PCR-Array analysis to compare the expression profile of
various genes involved during EMT transition between plastic and
mammospheres groups (Figure 3A). We found up-regulation of
Akt1 (2.44 fold); collagen, type 5a2 (Col5a2) (1.60 fold); integrin
alpha 5 (ITGAV) (1.99 fold); MMP9 (2.53 fold); Serpine 1
(3.98 fold); six-transmembrane epithelial antigen of prostate 1
(STEAP1) (2.01 fold), TCF4 (1.56 fold); twist (1.50 fold); trans-
membrane protein 132a (TMEM132a) (2.73 fold) and Wnt 5a
(1.81 fold) and down-regulation of regulator of G-protein signaling
2 (RGS2) (62%) among several other genes in mammospheres
compared to the plastic group (Figure 3A). Also, we found up-
regulation of macrophage stimulating 1 receptor (Mst1R) (1.92
fold); Nodal (2.5 fold) as well as Stat 3 (1.82 fold) genes in
mammospheres, which are highly implicated in migration and
motility of cells (Figure 3A). Next, we performed quantitative real-
time PCR analysis to confirm and validate the changes in EMT
gene signature from plastic and mammospheres groups (Figure 3B).
We found a significant increase in Akt1 (1.560.15 fold); ITGAV
(1.660.21 fold); MMP9 (1.760.26 fold); Serpine 1 (1.4860.23
fold); Snail (1.9260.17 fold) and Twist (1.8660.24 fold) as well as
a significant decrease in E-cad (80.268%) gene expression in
mammospheres compared to the plastic group (Figure 3B). Our
data, therefore, suggest that our initial observation of down-
regulation of VDR and concurrent induction of Snail expression
in mammospheres is associated with significant changes in gene
expression profiles that promote EMT.
Effect of Genetic Manipulation of VDR Expression on Key
EMT Regulators and the Mammosphere Forming
Capability in Breast Cancer Cells
To further explore the functional role of VDR in modulating
key proteins and genes involved during EMT transition and
correlate their possible association with the ability to form
mammospheres, we performed both VDR knock out (Figure 4A–
C) and VDR over-expression (OE) (Figure 4 D-F) experiments in
SKBR3 cells. Using VDR on-target plus pool of siRNAs directed
against human VDR, we were able to knock down ,75%
expression of VDR. Inhibition of VDR expression by siRNA pools
resulted in appreciable up-regulation of Snail but down-regulation
of E-cadherin (E-cad) proteins compared to the scrambled RNA
treated group (Figure 4A). We next, analyzed the gene expression
profile of key EMT markers from mammospheres isolated from
scrambled (Scram) as well as from VDR siRNA transfected cells.
We found a significant decrease in VDR (70.769%) and E-cad
(60.0613%) genes but significant up-regulation of Snail1
(1.8860.2 fold); fibronectin 1 (FN1) (1.560.15 fold); ITGAV
(1.4160.21 fold); MMP9 (2.9960.31 fold); Twist (1.7060.12 fold)
as well as PDGF (1.5260.27 fold) (Figure 4B). We next compared
mammosphere forming abilities of the cells treated either with
Scam or VDR siRNA. We found a significant increase in the
mammosphere forming ability of cells treated with VDR siRNA
(1.9360.27 fold) compared to the Scram RNA treated group
(Figure 4C).
We also performed VDR over-expression in SKBR3 cells using
human VDR ORF clone purchased from Origene. We were able
to significantly up-regulate VDR protein expression (4–5 fold) in
VDR OE group. This up-regulation of VDR protein expression
was associated with down-regulation of Snail but up-regulation of
E-cad protein (Figure 4D). Analyses of gene expression profile of
select EMT pathway genes between mammospheres isolated from
control vector and VDR OE groups demonstrate a significant up-
regulation of VDR (3.9860.34 fold) and E-cad (1.660.26 fold)
gene expression but significant down-regulation of Akt1
(61.069%); MMP9 (53.2612%); Notch1 (50.0621%); Snail1
(66.5611%); Twist (43.068%) and Wnt5b (51.4617%)
(Figure 4E). Also, VDR OE cells had significantly decreased
(2.84648 fold) ability to form mammospheres (Figure 4F).
Therefore, our combined data from VDR knock out as well as
VDR OE experiments in SKBR3 cells clearly suggest that
manipulation of VDR expression dictates the ability of cancer
cells to form mammospheres by regulation of Snail/E-cad-
mediated pathway, which is essential during EMT process.
Growth Factor Independence of VDR Down-regulation in
Mammospheres
Expression of VDR protein was assessed in SKBR3 cells grown
under mammosphere and plastic conditions either in presence or
absence of growth factors (GF) that included a combination of
EGF (10 ng/ml) and FGF (10 ng/ml). Under both conditions, the
level of VDR expression was not significantly different (Figure 5A)
within either group, suggesting that the down-regulation of VDR
mRNA and protein in mammosphere is independent of in-
cubation with the above doses of EGF and FGF. However, the
Vitamin D Receptor and Breast Cancer Stem Cells
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Figure 2. Selective down-regulation of VDR/RXR expression in mammospheres isolated from breast cancer cells A, Top panel: 50 mg
of total cell lysates isolated from breast cancer cell lines SKBR3 (left), MCF7 (middle) and HRas (right) cells grown under plas or
mam conditions and were analyzed for VDR and RXR protein expression by Western blot analysis. Bottom panel: Quantitative
densitometric analysis of VDR and RXR expression in SKBR3 (left), MCF7 (middle) and HRas (right) cell normalized to GAPDH (*, p#0.05; **, p#0.01). B,
Top panel: 50 mg of total cell lysates isolated from mammary epithelial HMLE cells grown under plas or mam conditions were analyzed for VDR and
Vitamin D Receptor and Breast Cancer Stem Cells
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level of VDR expression in mammosphere group was much lower
compared to the plastic group as expected (Figure 5A).
Inverse Relationship between VDR and CD44 Expression
in ALDH+ cells and Transplantable Xenografts
To further validate our initial findings that mammospheres
enriched in MCSCs express lower levels of VDR expression, we
isolated ALDH+ and ALDH2 populations from SKBR3 cells by
cell sorting and compared the levels of VDR and CD44 expression
between the groups. We found that ALDH+ population had
significantly lower (72.665.4%; p#0.01) levels of VDR expression
compared to the ALDH2 populations. On the other hand, CD44
was significantly up-regulated (8869%; p#0.01) in ALDH+
population (Figure 5B). We next compared the expression levels
of VDR and CD44 between a highly aggressive and transplantable
xenograft line (TX) obtained after injection of HRas cells in the
nude mice to that of a non-transplantable xenograft line (NTX).
VDR expression was significantly down-regulated (62.466.3%,
p#0.05), whilst CD44 protein expression was significantly up-
RXR protein expression by Western blot analysis. Bottom panel: Quantitative densitometric analysis of VDR and RXR expression normalized to GAPDH
(*, p#0.05; **, p#0.01). C, Real-time quantitative PCR analysis of VDR expression in SKBR3, MCF7 and HRas as well as in HMLE cells grown under plas
or mam conditions (*, p#0.05; **, p#0.01). D, Selective up-regulation of Snail in MCF7 and SKBR3 cells. Top panel; 50 mg of total cell lysates isolated
from MCF7 (left panel), SKBR3 (middle panel) or HMLE cells (right panel) grown under plas or mam conditions were analyzed for Snail expression by
Western blot analysis. Bottom panel: Quantitative densitometric analysis of Snail expression normalized to GAPDH (**, p#0.01).
doi:10.1371/journal.pone.0053287.g002
Figure 3. A, PCR Array Analysis of EMT-specific genes in SKBR3 cells grown under plas and mams conditions after 4 days. B,
Validation of PCR Array data by quantitative real time PCR analysis. Experiment was performed in triplicates from three different sets of experiments
(*, p#0.05; **, p#0.01).
doi:10.1371/journal.pone.0053287.g003
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regulated (4.860.44 fold, p#0.001) in TX compared to the NTX
(Figure 5C).
Selective Down-regulation of VDR Expression in
Aggressive TN Tumors Compared to the ER+ Tumors and
it’s Association with Increased Expression of CD44
To test whether VDR levels are down-regulated in more
aggressive tumors, VDR and CD44 expression was assessed in
fresh human tumor samples obtained from aggressive triple
Figure 4. A, Inhibition of VDR expression in SKBR3 cells by siRNA and analysis of VDR, Snail and E-cad protein expression. SKBR3
cells were transfected either with scrambled siRNA (Scram) or On-target smart pool VDR siRNA (siRNA) using standard techniques and protein
expression was analyzed by western blot analysis. B, Analysis of EMT-specific gene signature in Scam and VDR siRNA transfected cells (*, p#0.05; **,
p#0.01). C, Analysis of mammospheres forming capability in Scam and VDR siRNA transfected cells. 5,000 cells after transfection were plated on 24
well ultra-low attachment plates and total numbers of mammospheres formed were analyzed (**, p#0.01). D, Over-expression of full length human
VDR gene and analysis of VDR, Snail and E-cad protein expression by western blot. E, Analysis of EMT-specific gene signature in cells transfected
either with control vector or full-length human VDR (*, p#0.05; **, p#0.01). F, Analysis of mammospheres forming capability in cells transfected
either with control vector or VDR over-expressing (VDR OE) plasmid. 5,000 cells after transfection were plated on 24 well ultra-low attachment plates
and total numbers of mammospheres formed were analyzed (**, p#0.01).
doi:10.1371/journal.pone.0053287.g004
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negative (TN) and estrogen receptor positive (ER+) tumors
(Table 1). Western blot analyses of tumor specimens (6 TN and
6 ER+) suggested an inverse relationship between tumor aggres-
siveness and VDR expression (Figure 6A–B). TN breast tumors
expressed significantly lower VDR (76.466.2%) and higher CD44
(105.668.7%) expression compared to ER+ tumor groups
(Figure 6A–B).
Mammospheres are Resistant to Vitamin D Treatment
Breast cancer cells cultured in various concentrations of 1,25D
under high attachment conditions were highly sensitive to 1,25D,
which inhibited cell proliferation in both MCF7 (5863% at
0.001 nM and 7665% at 0.1 nM) and SKBR3 (34.566% at
0.1 nM) cells (Figure 7A). However, the proliferation of the
mammospheres as measured by their average diameter, did not
change significantly either at 4 or 7 days after treatment with
1,25D (0–100 nM) (Figure 7B). There was no significant difference
Figure 5. A, Analysis of VDR expression in SKBR3 cells grown under mam or plas conditions with or without growth factors (GF: EGF
plus FGF). 30 mg of cell lysates were electrophoretically separated and analyzed by western blot analysis using anti-VDR antibody. Membranes were
stripped and re-probed using anti-GAPDH antibody for loading controls. B (Left Panel), Analysis of VDR and CD44 protein expression in ALDH2 and
ALDH+ populations isolated from SKBR3 cells. 30 mg of cell lysates obtained from ALDH+ and ALDH2 cells were electrophoretically separated and
analyzed by western blot analysis using anti-VDR or anti-CD44 antibodies. Membranes were subsequently stripped and re-probed with anti-GAPDH
antibody for loading controls. B (Right Panel), Normalized densitometric ratios showing relative expression levels of VDR and CD44. C (Left Panel),
Analysis of VDR and CD44 protein expression in non-transplantable xenografts (NTX) and transplantable xenografts (TX). 30 mg of total cell lysates
obtained from non-transplantable xenografts (NTX) and transplantable xenografts (TX) were electrophoretically separated and analyzed by western
blot analysis using anti-VDR or anti-CD44 antibodies. Membranes were stripped and re-probed with anti-GAPDH antibody for loading controls (*,
p#0.05; **, p#0.01). C (Right Panel), Normalized densitometric ratios showing relative expression levels of VDR and CD44.
doi:10.1371/journal.pone.0053287.g005
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Figure 6. A, Analysis of VDR and CD44 protein expression in tumor biopsies from triple negative (TN) and estrogen receptor
positive (ER+) breast cancer patients. 50 mg lysates from 6 tumor samples each from TN and ER+ were analyzed for VDR and CD44 protein
expression by Western blot analysis. B, Normalized densitometric values for VDR and CD44 expression from TN and ER+ tumor patients (*, p#0.05; **,
p#0.01).
doi:10.1371/journal.pone.0053287.g006
Table 1. Patient and tumor sample characteristics.







TN1/CHTN white 48 negative IIB Infiltrating mammary carcinoma 6.2
TN2/CHTN white 78 positive IA Infiltrating mammary carcinoma 5.3
TN3/CHTN white 86 negative IIA Infiltrating mammary carcinoma 3
TN4/CHTN white 75 positive IIIA Invasive ductal carcinoma 5.7
TN5/NDRI white 46 negative IIA Invasive ductal carcinoma 2.5
TN6/NDRI white 68 positive IA Invasive ductal carcinoma 4.8
ER+1/UCLA white 48 negative IIA Infiltrating ductal carcinoma 4.8
ER+2/UCLA white 58 positive IIB Infiltrating lobular carcinoma 4.5
ER+3/UCLA white 51 positive IIIC Infiltrating ductal carcinoma 4.2
ER+4/CHTN white 59 positive IIIA Infiltrating ductal adenocarcinoma 6.2
ER+5/CHTN white 57 positive IV Invasive mammary carcinoma(multifocal) 7.3
ER+6/CHTN white 59 positive IIIA Infiltrating mammary carcinoma 3.5
Triple negative (TN) and estrogen receptor positive tumor (ER+) human breast cancer tissues were obtained from various sources. CHTN, Co-operative Tissue Network,
Breast tumor and tissue repository at UCLA (UCLA) and National Drug Research Interchange (NDRI).
doi:10.1371/journal.pone.0053287.t001
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in expression of mRNA for the vitamin D-activating enzyme
CYP27B1 between the groups; however, there was a significant
decrease in expression of the vitamin D-catabolic enzyme
CYP24A1 (7966%) in mammospheres (Figure 7C). Synthesis of
24,25D (CYP24A1 activity) and 1,25D (CYP27B1 activity) from
precursor 25D in cells grown under both plastic and mammo-
spheres conditions for 4 days was studied by HPLC analysis
(Figure 7D). There was a significant decrease in both CYP24A1
and CYP27B1 activities in mammosphere vs. plastic cultures
(Figure 7D).
Nitric Oxide Induced MKP-1 Expression and pERK1/2
Dephosphorylation in Mammospheres Isolated from
SKBR3 cells and Potentiated the Growth Inhibitory Effects
of 1,25D both In Vitro and In Vivo
Histone deacetylase (HDAC) inhibitors are reported to augment
the growth inhibitory effects of 1,25D in a TN breast cancer cell
line, MDA-MB-231 by releasing nitric oxide (NO) [21]. We have
previously demonstrated that NO treatment of breast cancer cells
leads to the induction of MKP-1 followed by dephosphorylation of
ERK1/2, which was essential for inducing apoptosis in breast
cancer cells [22]. More recently, we also found that stable nuclear
pERK1/2 was present at basal level in these mammospheres
Figure 7. A, Effect of 1,25D treatment on MCF7 (left) and SKBR3 (right) cell proliferation. Cells were treated with 1,25D (0–0.1 nM) and
allowed to proliferate for 4 days under high attachment conditions and cell numbers were counted by trypan blue method (*, p#0.05; **, p#0.01).
Medium was replaced after every 48 hrs with appropriate concentrations of 1,25D. B, SKBR3 (26104) cells were plated under mammosphere
conditions on a 12-well ultra-low attachment plates in presence of different concentrations of 1,25D (0–0.1 nM) and allowed to grow under
mammosphere conditions for 4 or 7 days and sphere diameters were measured. Appropriate concentrations of 1,25D were additionally
supplemented in the culture medium after every 48 hours. Left Panel: Micrographs were taken at 1006magnification. Right Panel: Quantitative
analysis of average diameter computed from 20 different fields from each treatment group. C, Quantitative real-time PCR analysis of Cyp27 B1 and
Cyp24A1 mRNA expression from MCF-7 cells grown under plas or mam conditions after 4 days of plating (**, p#0.01). D, HPLC analysis of 24,25D3
and 1,25D synthesis in cells grown under plastic or mammos conditions from MCF-7 cells after 4 days of plating (*, p#0.05; **, p#0.01).
doi:10.1371/journal.pone.0053287.g007
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(Pervin et. al, under review). Accordingly, we tested whether
a combination of NO and 1,25D would be more effective in
inhibiting the proliferation of mammospheres in vitro and tumor
size in nude mice in vivo. DETA NONOate treatment led to the
induction of MKP-1 protein expression in a time-dependent
manner, and this effect was associated with a concomitant
decrease in pERK1/2 expression in mammospheres (Figure 8A,
top panel and bottom panel). Cells treated either with 1,25D
(0.01 nM) and DETA NONOate alone or in combination were
grown under mammosphere conditions for 4 days after which the
sphere diameters were measured. 1,25D treatment alone did not
significantly change the average size of mammospheres. However,
in combination with DETA NONOate, it significantly decreased
the mammosphere size (63.4618.1%) (Figure 8B). A significant
decrease in mammosphere size (30.168.4%) was also observed
with DETA NONOate treatment alone (Figure 8B). By contrast,
when cells were allowed to grow in plastic either in the presence of
1,25D (32.0463.7%), DETA NONOate (25.862.4%) alone or in
combination (58.364.4%), significant inhibition in cell prolifera-
tion of HRas cells was observed after 4 days (Figure 8C). When
16105 cells obtained from dissociated mammospheres after 4 day
treatments with DETA NONOate and 1,25D either alone or in
combination were injected into nude mice, there was a significant
inhibition of tumor volume compared to the control group after 6
weeks (con vs. DETA+1,25D: 39.268.2%) and 8 weeks (con vs.
1,25D: 26.364.4%; con vs. DETA+1,25 D: 43.466.3%)
(Figure 8D). On the other hand, there was only 12.362.2%
inhibition in tumor volume in DETA (NO-donor) treated
mammosphere group compared to the control group after 8
weeks of injection (Figure 8D).
Discussion
We show that mammospheres enriched in ALDH+ cells from
breast cancer cell lines express a clinically relevant ESAhigh,
CD44high, and CD24low cell phenotype that can be passaged
multiple times and that can form transplantable xenografts in nude
mice. An important finding of this study was the down-regulation
of VDR/RXR in the mammospheres from breast cancer cell lines
when compared to differentiated cells grown on high attachment
plates. This effect was independent of growth factors present in the
mammosphere medium. Although there are reports that VDR
levels are low in aggressive TN breast cancer cell lines, to our
knowledge, this is the first report demonstrating the suppression of
this receptor in mammospheres. It has been reported that VDR
deletion results in a marked accumulation of hematopoietic stem
cells in the spleen that can be reversed by calcium dietary
supplementation [23].
Further, our studies showed that VDR expression was
suppressed while CD44 was up-regulated in transplantable
xenografts (TX), ALDH+ population enriched in MCSCs as well
as in aggressive breast tumors. In breast carcinomas, CD44 has
been identified as a key cell-surface marker for various cancer stem
cells. CD44 expression in human breast cancer cells enhances self-
renewal, mammosphere growth as well as drug resistance [24–27].
The ability of vitamin D to suppress CD44 expression in breast
cancer cells may suggest that manipulation of vitamin D levels may
reduce tumor burden. Our findings of down-regulation of VDR
expression in aggressive TN tumors compared to ER+ tumors has
limitations as the data is derived only from a limited set of tumor
biopsies and therefore, should be interpreted carefully. Another
indication that vitamin D regulates stem cells comes from a study
where p63, which regulates the proliferative potential of epithelial
stem cells, was found to specifically bind to VDR promoter and
transcriptionally induce the receptor [28]. Unlike MCSCs and
aggressive breast tumors, high levels of functional VDR have been
found in normal mammary glands mediating the effects of 1,25D
on growth and differentiation of these cells [29–30]. Increased
numbers of undifferentiated mammary gland terminal end buds
have been reported in VDR null mouse, suggesting that vitamin D
promotes differentiation during early mammary gland develop-
ment [30]. In our study, we observed that expression of VDR in
the mammary epithelial cells grown on high attachment plastic
plates as well as under mammosphere conditions were compara-
ble. Activities of the enzymes that degrade (CYP24A1) and
activate vitamin D (CYP27B1) were suppressed in MCSCs, but
not in cancer cells propagated under high attachment conditions.
This result contradicts other reports where CYP24A1 expression
has been shown to be augmented in carcinomas compared to
benign lesions [31]. The reason for these differences is not clear.
Mammospheres isolated from breast cancer cell lines were
resistant to 1,25D treatment, which contrasts its effects on cancer
cells grown under high attachment conditions. It has been
demonstrated that MCSCs are not only resistant to various
therapies, but that chemotherapy increases the number of stem
cells in residual tumors [12]. However, a number of dietary
compounds have been found to directly or indirectly affect cancer
stem cell self-renewal pathways including pancreatic, breast cancer
and melanoma [32–33]. High levels of circulating 25D as found in
epidemiological studies, have been associated with reduced risk of
ovarian and pancreatic cancers [34–35]. Accordingly, it may be
important to combine vitamin D with other compounds to
increase therapeutic efficacy. Since high concentrations of active
1,25D alone produced only marginal effects on mammosphere
proliferation, it will be important to synergize this therapeutic
molecule with proven therapeutic agents.
Our data provides a direct effect of manipulation of VDR
expression either by siRNA-mediated knock down of VDR or
over-expression of full length human VDR in mammospheres on
gene and protein expression of Snail (mesenchymal) and E-cad
(epithelial), two key regulators of EMT pathway. The Snail family
of transcription factors are known to suppress VDR expression
and are key regulators of epithelial to mesenchymal transition
(EMT), a process in which epithelial cells lose their apical and
basolateral polarity and degrade basement membrane extracellu-
lar matrix components during tumor invasion [15,36–37]. Loss of
VDR expression during colon cancer progression is related to
Snail up-regulation, suggesting that high levels of Snail may be
responsible for the failure of therapy with vitamin D analogues in
patients [38]. Disruption of VDR-mediated signaling has been
reported for several neoplastic cell lines, and is not only restricted
to Snail-mediated mechanisms. Deregulation of VDR-associated
co-activators and repressors has been associated with impaired
sensitivity to 1,25D in a variety of breast and prostate cancer cell
lines [39].
Expression of Snail was up-regulated in mammospheres from
breast cancer cells, but was lower in cells on high attachment
plates. Inhibition of VDR expression was associated with
significant decrease in E-cad (epithelial marker) but a simultaneous
increase in Snail1 and Twist among other mesenchymal markers.
The mammosphere forming capability of cells were found to be
significantly increased after siRNA-mediated inhibition of VDR
expression in SKBR3 cells. Similarly, over-expression of VDR
significantly reduced the ability of these cells to form mammo-
spheres, an effect which was associated with inhibition of Snail 1
but induction of E-cad. Our data presented here clearly suggest
that elevated expression of Snail may be one of the underlying
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mechanisms for decreased VDR expression and CYP24A1 activity
observed in mammospheres.
Various strategies have been proposed to counteract aberrant
responses to 1,25D in neoplastic cells. For example, VDR
signaling is known to be epigenetically modified with histone
Figure 8. A, Top panel: MKP-1 induction and dephosphorylation of pERK1/2 in DETA NONOate (DETA) treated HRas
mammospheres. Bottom Panel: Immunofluorescence analysis of MKP-1 and pERK1/2 in control and DETA (0.3 mM) treated mammospheres
after 24 hrs. B, Top panel: Photomicrographs of HRas cells plated under mammosphere conditions and allowed to grow in medium containing either
1,25D (0.1 nM) and DETA (0.3 mM) alone or in combination for 5 days. Bottom panel; Average diameter of mammospheres computed from 20
different fields from each treatment groups (*, p#0.05; **, p#0.01). C, 56105 HRas cells were allowed to seed on T-25 flasks and treated with 1,25D
and DETA either alone or in combination. Total number of cells were counted after 5 days (*, p#0.05; **, p#0.01). D, HRas cells were plated under
mammospheres conditions and treated with DETA (0.3 mM), or 1,25D (0.1 nM) either alone or in combination for 3 days. Mammospheres were
dissociated and 16105 cells from each treatment groups were injected into nude mice and tumor volumes were analyzed at various time points (1–8
weeks) (*, p#0.05; **, p#0.01 compared to the Con group).
doi:10.1371/journal.pone.0053287.g008
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deacetylase (HDAC) inhibitors, leading to enhanced anti-pro-
liferative effects of 1,25D [38]. As HDAC inhibitors are reported
to release NO [21], the findings that 1,25D in combination with
HDAC inhibitors resulted in re-expression of anti-proliferative
target genes in TN breast cancer cell line MDA-MB-231 [40]
support our findings that combinatorial therapy using 1,25D and
low physiological dose of NO may reduce the proliferative ability
of MCSCs and thereby inhibit tumor initiation and tumor mass.
We have previously reported that aggressive breast cancer cell
lines are highly sensitive to NO- mediated cytostasis and apoptosis
[41]. NO induces MKP-1, which dephosphorylates ERK1/2 to
facilitate Bax integration in to the mitochondrial membrane and
increase cytochrome c release from the mitochondria [22,42].
There are reports that constitutive activation of ERK1/2-MAPK
signaling pathway impairs vitamin D signaling in human prostate
epithelial cells [43]. In this study, we found only high concentra-
tions of NO donor, DETA-NONOate, were able to reduce the
proliferation of mammospheres from breast cancer cells. However,
by demonstrating similar results with a combination of low
concentration of NO and 1,25D our data provide an alternative
strategy for correcting corrupted VDR signaling in breast cancer
cells, at least in the context of MCSCs. In future studies it will be
interesting to explore the broader translational potential of various
NO-donors in combination with vitamin D metabolites and
analogs for the treatment of aggressive breast tumors.
In summary, data presented here show for the first time that
VDR-mediated signaling in MCSCs enriched mammospheres
play a key role in dictating their overall oncogenic program by
regulating Snail/E-cad/EMT pathway. Mammospheres exhibit
relative insensitivity to the anti-proliferative effects of vitamin D
and abrogation of this effect using combinatorial therapies may
provide new translational strategies for the use of vitamin D in
treating breast cancer. Combinations of 1,25D or its synthetic
analogs with other anti-cancer agents have demonstrated syner-
gistic interactions in a variety of studies [44–45]. However, several
concerns related to the hypercalcemic effects associated with very
high doses of 1,25D used to treat breast tumor patients exist.
Dexamethasone is reported to significantly improve 1,25D anti-
tumor efficacy in vitro and in vivo through direct effects on VDR
[46]. Combination of 1,25D with aromatase inhibitors has been
shown to enhance anti-proliferative effects on breast cancer cells
[47–48]. The expression and function of aromatase and other
estrogenic enzymes in MCSCs and their potential modulation by
vitamin D metabolites is yet unclear but is likely to provide
a fruitful avenue for future studies. Use of MCSCs in vitro and
in vivo provides invaluable model system to explore the molecular
mechanisms and efficacy of combinatorial therapies and may
provide new translational strategies for the use of vitamin D.
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